Published in Proc Natl Acad Sci U S A on July 20, 1999
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood (2007) 2.68
Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol (2009) 2.31
Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med (2012) 2.11
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer (2006) 2.09
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther (2010) 1.64
Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res (2007) 1.56
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol (2000) 1.52
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A (2008) 1.49
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med (2010) 1.40
Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood (2008) 1.34
Dendritic cells and immunity against cancer. J Intern Med (2011) 1.32
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med (2004) 1.32
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer (2006) 1.29
Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med (2003) 1.28
Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med (2001) 1.22
Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer (2003) 1.21
Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens. J Exp Med (2001) 1.20
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood (2005) 1.19
An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood (2007) 1.18
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Front Immunol (2014) 1.14
Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med (2000) 1.12
Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A (2010) 1.06
HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A (2014) 1.06
Race between retroviral spread and CD4+ T-cell response determines the outcome of acute Friend virus infection. J Virol (2009) 1.05
Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J Immunol (2008) 1.03
Cytosolic DNA-activated human dendritic cells are potent activators of the adaptive immune response. J Immunol (2011) 1.03
Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res (2013) 1.02
Regulatory T cells control the Th1 immune response in murine crescentic glomerulonephritis. Kidney Int (2011) 1.01
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia (2014) 1.00
The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann N Y Acad Sci (2009) 0.99
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol (2012) 0.97
Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood (2009) 0.96
Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo. J Clin Invest (2004) 0.96
TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin Dev Immunol (2012) 0.94
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol (2012) 0.94
Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biol Blood Marrow Transplant (2007) 0.92
Tumor rejection by modulation of tumor stromal fibroblasts. J Exp Med (2003) 0.91
Modulation of antitumor responses by dendritic cells. Springer Semin Immunopathol (2005) 0.91
CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages. Immunology (2007) 0.90
An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest (2004) 0.90
Dendritic cells: are they clinically relevant? Cancer J (2010) 0.90
CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol (2008) 0.90
MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother (2012) 0.88
Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med (2002) 0.88
The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells. Clin Med Insights Oncol (2011) 0.87
Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands. EMBO Rep (2009) 0.86
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin Immunol (2009) 0.86
Phorbol myristate acetate and Bryostatin 1 rescue IFN-gamma inducibility of MHC class II molecules in LS1034 colorectal carcinoma cell line. Cancer Cell Int (2003) 0.84
Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology (2005) 0.83
HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol (2011) 0.83
Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br J Cancer (2001) 0.82
MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients. PLoS One (2012) 0.82
Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation. Mol Ther (2009) 0.81
Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. J Transl Med (2013) 0.81
Anti-tumour effects of polysaccharides isolated from Artemisia annua L by inducing cell apoptosis and immunomodulatory anti-hepatoma effects of polysaccharides. Afr J Tradit Complement Altern Med (2013) 0.80
Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells. PLoS One (2015) 0.80
Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. Prostate (2002) 0.79
Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. Clin Dev Immunol (2010) 0.79
Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer. J Virol (2000) 0.79
Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions. J Interferon Cytokine Res (2016) 0.79
A20 controls macrophage to elicit potent cytotoxic CD4(+) T cell response. PLoS One (2012) 0.78
Using magnetic resonance imaging to evaluate dendritic cell-based vaccination. PLoS One (2013) 0.78
Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J Exp Med (2016) 0.78
Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Head and Neck Squamous Cell Carcinoma. Transl Oncol (2016) 0.78
CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA. J Virol (2011) 0.77
Tumor protective activity of CD4+ but not of CD8+ T cells in DNA-vaccinated mice challenged with bcr-abl-transformed cells. Clin Dev Immunol (2013) 0.77
Benign autoimmunity to combat malignancy. Clin Exp Immunol (2001) 0.77
Cancer immunotherapy: moving forward with peptide T cell vaccines. Curr Opin Immunol (2017) 0.76
MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer. Haematologica (2012) 0.76
Generation of more effective cancer vaccines. Hum Vaccin Immunother (2013) 0.76
Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen. Immunol Cell Biol (2016) 0.76
Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display. Oncotarget (2016) 0.76
Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy. J Immunol (2015) 0.75
Comparative analysis of CD4+ and CD8+ T cells in tumor tissues, lymph nodes and the peripheral blood from patients with breast cancer. Iran Biomed J (2015) 0.75
CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8(+) T-cell responses. Eur J Immunol (2015) 0.75
Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. PLoS One (2017) 0.75
Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER(pos)/HER2(pos) early breast cancer. Oncoimmunology (2016) 0.75
Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 13.23
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol (1994) 10.03
Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature (1985) 9.18
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J Exp Med (1993) 4.06
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med (1985) 2.65
A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci U S A (1990) 2.50
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med (1981) 2.50
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A (1989) 2.40
A unique tumor antigen produced by a single amino acid substitution. Immunity (1995) 2.33
Interferon-gamma: biology and role in pathogenesis. Adv Immunol (1996) 2.08
Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem (1997) 2.05
Cooperative interaction between interferon (IFN) stimulus response element and kappa B sequence motifs controls IFN gamma- and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter. J Biol Chem (1993) 1.88
Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer (1989) 1.80
Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med (1989) 1.76
Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med (1982) 1.73
Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med (1999) 1.70
Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood (1997) 1.63
Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A (1996) 1.52
Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity (1998) 1.49
Hyaluronan fragments synergize with interferon-gamma to induce the C-X-C chemokines mig and interferon-inducible protein-10 in mouse macrophages. J Biol Chem (1998) 1.43
Multiple tumour-specific antigens expressed on a single tumour cell. Nature (1983) 1.36
Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol (1998) 1.32
Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res (1990) 1.28
Antiangiogenic gene therapy. Proc Natl Acad Sci U S A (1998) 1.18
The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science (1990) 1.13
Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int J Cancer (1994) 1.12
Inhibition of cellular responsiveness to interferon-gamma (IFN gamma) induced by overexpression of inactive forms of the IFN gamma receptor. J Biol Chem (1993) 1.05
Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells. J Exp Med (1986) 1.04
Biological implications of HLA-DR expression in tumours. Scand J Immunol (1995) 0.96
Characterization and use of monoclonal and polyclonal antibodies against the mouse interferon-gamma receptor. J Leukoc Biol (1992) 0.92
Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo. J Immunol (1995) 0.86
The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens. J Leukoc Biol (1987) 0.81
Role of host antigen receptor-bearing and antigen receptor-negative cells in immune response to rat adenocarcinoma 13762. J Immunol (1996) 0.80
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (1990) 14.46
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science (1988) 7.96
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A (1985) 7.15
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med (1982) 6.56
The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol (1993) 5.88
Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol (1989) 5.39
The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol (1997) 4.76
Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. J Immunol (1989) 4.70
Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol (1985) 4.44
Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli. Infect Immun (1991) 4.18
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol (2001) 4.16
Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med (1984) 4.00
Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. Cell (1985) 3.81
Activation of oxidative stress genes by mutations at the soxQ/cfxB/marA locus of Escherichia coli. J Bacteriol (1991) 3.75
Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A (1996) 3.62
A T cell-independent mechanism of macrophage activation by interferon-gamma. J Immunol (1987) 3.55
Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. Immunol Rev (1991) 3.49
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol (1980) 3.41
Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med (1995) 3.37
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A (1994) 3.34
Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature (1994) 3.34
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell (1998) 3.25
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet (1999) 3.12
Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science (2001) 3.11
Gamma interferon limits access of Listeria monocytogenes to the macrophage cytoplasm. J Exp Med (1989) 3.08
In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect Immun (1992) 3.07
Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med (1993) 3.06
Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci U S A (1988) 3.04
Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med (1974) 2.93
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88
Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J (1994) 2.82
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Release of nitric oxide during the T cell-independent pathway of macrophage activation. Its role in resistance to Listeria monocytogenes. J Immunol (1993) 2.73
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68
Inhibition of tumor growth by elimination of granulocytes. J Exp Med (1995) 2.65
Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci U S A (1986) 2.63
Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. J Immunol (1983) 2.61
A prospective, multi-center clinical trial of the Taylor intragastric balloon for the treatment of morbid obesity. Am J Gastroenterol (1990) 2.59
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci U S A (2001) 2.56
Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science (2001) 2.52
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med (1979) 2.39
A unique tumor antigen produced by a single amino acid substitution. Immunity (1995) 2.33
Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med (1994) 2.33
CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology (2001) 2.16
Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. J Exp Med (1976) 2.13
A molecular concept of the properdin pathway. Proc Natl Acad Sci U S A (1976) 2.09
Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice. Proc Natl Acad Sci U S A (1992) 2.06
Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol (1994) 2.05
Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem (1997) 2.05
A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A (1990) 2.03
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med (1997) 2.00
Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. Immunity (1995) 2.00
Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity. J Exp Med (1981) 1.99
Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med (1997) 1.96
Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A (2001) 1.96
Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A (1995) 1.94
Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med (1997) 1.92
Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science (1995) 1.90
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med (1983) 1.83
Seroepidemiology of hepatitis A infection in India: changing pattern. Indian J Gastroenterol (2001) 1.82
Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med (1992) 1.81
Identification of a T cell hybridoma that produces large quantities of macrophage-activating factor. J Exp Med (1982) 1.81
Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem (1999) 1.77
Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med (1989) 1.76
Role of endogenous gamma interferon in host defense against Chlamydia trachomatis infections. Infect Immun (1989) 1.74
Stercoral perforation of the colon. Concepts of operative management. Am Surg (1985) 1.73
Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. Proc Natl Acad Sci U S A (1983) 1.73
Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med (1982) 1.73
Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol (1989) 1.70
HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. Hepatology (1992) 1.68
Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. Genes Dev (1992) 1.68
Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med (1995) 1.67
Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest (1989) 1.67
Generation of monoclonal antibodies to murine IL-1 beta and demonstration of IL-1 in vivo. J Immunol (1991) 1.65
Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun (1993) 1.65
Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol (1980) 1.65
Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J Biol Chem (1996) 1.64
Monoclonal antibodies to murine IL-1 alpha. Production, characterization, and inhibition of membrane-associated IL-1 activity. J Immunol (1988) 1.63
CD8 T cells can protect against an intracellular bacterium in an interferon gamma-independent fashion. Proc Natl Acad Sci U S A (1992) 1.61
Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes Cells (1998) 1.59
Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. J Infect Dis (2000) 1.58
C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface. J Immunol (1983) 1.52
Phosphorylated interferon-alpha receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 kDa STAT2 protein. EMBO J (1996) 1.51
Antibody-independent activation of the alternative complement pathway by measles virus-infected cells. Proc Natl Acad Sci U S A (1980) 1.48
Effect of antibodies directed against complement receptors on phagocytosis by polymorphonuclear leukocytes: use of iodination as a convenient measure of phagocytosis. J Immunol (1985) 1.47
Reusable needles--a major risk factor for acute virus B hepatitis. Trop Doct (1993) 1.45
ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. J Biol Chem (2001) 1.44
Suppression by autogenous complementary idiotypes: the priority of the first response. J Exp Med (1976) 1.43
Regulation of IFN-alpha/beta genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN-alpha/beta. Genes Cells (1996) 1.42